MacroGenics (MGNX) Projected to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is expected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.0779) per share and revenue of $59.1370 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). The firm had revenue of $20.77 million during the quarter, compared to the consensus estimate of $15.24 million. MacroGenics had a negative net margin of 44.79% and a negative return on equity of 147.80%. On average, analysts expect MacroGenics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MacroGenics Trading Down 3.9%

MGNX stock opened at $3.92 on Wednesday. The business’s 50-day moving average price is $4.23 and its two-hundred day moving average price is $3.35. The firm has a market cap of $249.16 million, a PE ratio of -3.56 and a beta of 1.20. MacroGenics has a 1-year low of $1.29 and a 1-year high of $5.08.

Hedge Funds Weigh In On MacroGenics

A number of large investors have recently added to or reduced their stakes in MGNX. LPL Financial LLC raised its position in MacroGenics by 181.2% in the 4th quarter. LPL Financial LLC now owns 65,125 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 41,967 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in MacroGenics by 11,970.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 43,814 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 43,451 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in MacroGenics by 63.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 42,382 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 16,400 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of MacroGenics by 99.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 104,751 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 52,326 shares in the last quarter. Finally, Sei Investments Co. bought a new position in shares of MacroGenics during the 2nd quarter worth approximately $38,000. Institutional investors own 96.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MGNX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a research report on Wednesday, August 5th. Barclays boosted their price objective on MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.50.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.